Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2008 / Cilt: 18 - Sayı: 1

The significance of C ERBB, EMA and B72.3 expression of hyperplastic endometrium versus neoplastik endometrium

Hiperplastik/neoplastik endometriyum ayrımında CERBB2, EMA, B72.3' ün yeri

Pages
8–14
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

B72.3 may be concerned as a spesific marker for differentiation of neoplastic endometrium versus nonneoplastic endometrial processes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: Our aim is to predict the position of the proto-oncogen c erbB2 and the epithelial markers EMA and B72.3 to differenciate hyperplastic endometrium from neoplastic one.
📊
Key Findings & Data:METHODS: Endometrial biopsy is performed to patients with menometroragy between September 2003-March 2004 at TCSB Tepecik Obstetrics and Gynecology Teaching Hospital. 21 cases (group-I) of histopathologically diognosed as endometrial cancer, 10 cases (group-II) of complex endometrial hyperplasia without atypia and resting 17 cases (group-Ill) of endometrium project proliferative and secretory changes are comperatively evaluated for immunohistochemical expression of c erbB2, EMA, B72.3.
💡
Conclusion & Impact:B72.3 may be concerned as a spesific marker for differentiation of neoplastic endometrium versus nonneoplastic endometrial processes.
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

AIM: Our aim is to predict the position of the proto-oncogen c erbB2 and the epithelial markers EMA and B72.3 to differenciate hyperplastic endometrium from neoplastic one. METHODS: Endometrial biopsy is performed to patients with menometroragy between September 2003-March 2004 at TCSB Tepecik Obstetrics and Gynecology Teaching Hospital. 21 cases (group-I) of histopathologically diognosed as endometrial cancer, 10 cases (group-II) of complex endometrial hyperplasia without atypia and resting 17 cases (group-Ill) of endometrium project proliferative and secretory changes are comperatively evaluated for immunohistochemical expression of c erbB2, EMA, B72.3. Positive cases are semiquantitatively interpreted for positivity pattern and staining intensity. Kruskal-Wallis and Mann Whitney U tests are used in comparison and statistical evaluation of the groups. RESULTS: While all cases in group II (n=10) and group III (n=17) were negative for c erbB2 protooncogen; 2 cases in neoplasia group I (n=21) were focally positive on cytoplasmic membrane. The only statistical difference was detected on staining intensity of EMA in neoplasia group (group I) versus the other groups (group Il+group III) through staining pattern, staining intensity and pattern+intensity (p=0,018). B72.3 expression displayed high statistical significance (p=0,001) in discriminating neoplastic/nonneoplastic endometrium and hyperplastic (complex endometrial hyperplasia)/neoplastic endometrium for both staining pattern and intensity variables. CONCLUSION: Although seems to be useful at first sight, immunohistochemical staining with c erbB2 oncogen was not statistically significant in discrimination of hyperplastic versus neoplastic endometrium. EMA seems to be useful to differentiate neoplasia from the other nonneoplastic processes depending on the staining intensity. B72.3 may be concerned as a spesific marker for differentiation of neoplastic endometrium versus nonneoplastic endometrial processes.

Özet

AMAÇ: Hiperplastik endometriyumu neoplastik olandan ayırmada c erbB2 proto-onkogeni ile EMA ve B72.3 epitelyal işaretleyicilerinin yerini belirlemektir. YÖNTEM: 2003 Eylül-2004 Mart tarihleri arasında menometroraji şikayeti ile Ege Doğumevi ve Kadın Hastalıkları Hastanesi 4. Kadın Doğum kliniğine gelen hastalara endometriyal biyopsi yapıldı. Histopatolojik olarak 21 olgu (grup-I) endometriyal karsinom, 10 olgu (grup-II) kompleks atipisiz endometriyal hiperplazi, kalan 17 olgu (grup-III) ise proliferasyon ve sekresyon özellikleri gösteren endometriyum olarak tanımlandı ve bu olguların tümüne c erbB2, EMA, B72.3 imundokukimyasal paneli uygulandı. Pozitif olgular yarıkantitatif olarak pozitivite patemi ve boyanma şiddetine göre gruplandırıldı. Gruplar istatistiksel olarak Kruskal-Wallis ve Mann Whitney U testleri ile karşılaştırılıp, değerlendirildi. BULGULAR: Grup II (s= 10) ve grup III (s= 17) olgularının tümü c erbB2 proto-onkogeni için boyanmazken, grup I (s=21) neoplazi olgularından 2'si sitoplazmik membranda fokal olarak pozitivite gösterdi. Neoplazi grubunun (grup-I) EMA boyanma paterni, boyanma şiddeti ve patern+şiddet karşılaştırması arasında sadece boyanma şiddeti açısından diğer gruplara göre (grup-II+grup-III) istatistiksel olarak anlamlı düzeyde farklılık gösterdiği saptandı (p=0,018). B72.3' nin varlığı neoplastik/neoplastik olmayan endometriyum ve hiperplastik (kompleks atipili-atipisiz hiperplazi)/neoplastik endometriyum ayrımında hem boyanma paterni hem de boyanma şiddeti açısından istatistiksel olarak ileri derecede anlamlı bulundu (p=0,00.1). SONUÇ: İlk bakışta c erbB2 onkogeninin imundokukimyasal olarak gösterilmesi hiperplastik/neoplastik endometriyum ayrımında kullanışlı gibi görünse de bu bulgu istatistiksel olarak doğrulanmamıştır. EMA, boyanma yoğunluğu açısından neoplastik lezyonları neoplastik olmayandan ayırmada anlamlı (p:0.001) görünmektedir. İmundokukimyasal olarak B72.3 neoplastik endometriyumu neoplastik olmayan endometriyal süreçden ayırmada özgün bir işaretleyici gibi görünmektedir (p=0.001).

🔖

Cite This Article

TEKİN, L., BAŞKESEN, N., YARDIM, B. G., BAYOL, Ü., MIZRAK, T., TANER, C. (2008). The significance of C ERBB, EMA and B72.3 expression of hyperplastic endometrium versus neoplastik endometrium. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 18 - Sayı: 1, 8–14. https://ajindex.com/articles/268590

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ronnett BM, Zaino RJ, Elleson LH, Kurman R J; Endometrial carcinoma. In Kurman RJ, ed. Blaustein's Pathology of the female genital tract. Fifth edition, Baltimore, Springer-Verlag. 2002; 501-59
  2. Crum CP; Female genital tract. In Kumar V, Abbas K.A, Fausto N. Pathologic Basis of Disease. 7th edition. Philadelphia, Pennsylvania 2005; 1059-1117
  3. Gitsch G,Hanzal E, Jensen D, Hacker NF; Endometrial cancer in premenaposal women 45 years old and younger. Obstet Gynecol 1995; 85-504-8
  4. Esteller M, Garcia A, Pakones JNM, Cabero A, Reventos J; Detection of c erbB2/neu and fibroblast growth factor-3/FNT-2 but not epidermal growth factor receptorgene amplification in endometrial cancer by differential polymerase chain reaction.Cancer 1995; 75: 2139-46
  5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL; Human breast cancer: Correlation of relaps and survival with amplification of Her-2/neu oncogene. Science 1987; 235:177-82
  6. Berhuck A, Kamel A, Whitaker R, et al: Overexpression of Her-2/neu is associated with poor survival in advanced epithelial ovarian cancer: Cancer Res 1990; 50: 4087-91
  7. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the Her2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707-12
  8. D'Emilia J, Bulovas K, D'Ercole K, etal. Expression of the c erbB2 gene product (pi85) at different stages of neoplastic progression in the colon. Oncogene 1989; 4-1233
  9. Nielsen AL, Nyholm HCJ: p53 protein ande cerbB2 protein (pi 85) expression in endometrial adenocarcinoma of endometrioid type: an immunohistochemical examination on parafin sections. Am J Clin Pathol 1994 Jul: 102 (1): 76-9
  10. Pres MF, Pike MC, Chazin VR. et al: Her2/neu expression in node-negative breast cancer. Direct tissue guantition by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993; 53:4960
  11. Brys M, Semezuk A, Rechberger T, Krajewska WM: Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium. Oncol Rep. 2007 Jul: 18(1):261-5
  12. Reinartz JJ, George E, Lingren BR, Niehans GA; Expression of p53, transforming growth factor alpha, epidermal growth factor receptor and c erbB2 in endometrial carcinoma and correlation with survival and know predictors of survival. Hum Pathol 1994; 25:1075-83
  13. Singleton TP, Strickler JG; Clinical and pathologicic significance of the c erbB2 (Her2/neu) oncogene. Pathol Annu 1992;27:165-90
  14. Borst